348 related articles for article (PubMed ID: 19808056)
1. Clinical management of HIV-1 resistance.
Paredes R; Clotet B
Antiviral Res; 2010 Jan; 85(1):245-65. PubMed ID: 19808056
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Current status and challenges of antiretroviral research and therapy.
Esté JA; Cihlar T
Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390
[TBL] [Abstract][Full Text] [Related]
4. The evolution of HIV treatment guidelines: current state-of-the-art of ART.
Zolopa AR
Antiviral Res; 2010 Jan; 85(1):241-4. PubMed ID: 19883695
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies for highly treatment-experienced HIV-infected patients.
Luber AD
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):815-23. PubMed ID: 16207173
[TBL] [Abstract][Full Text] [Related]
6. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.
McColl DJ; Chen X
Antiviral Res; 2010 Jan; 85(1):101-18. PubMed ID: 19925830
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of human immunodeficiency virus drug resistance: an update.
Menéndez-Arias L
Antiviral Res; 2010 Jan; 85(1):210-31. PubMed ID: 19616029
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice.
Imaz A; Falcó V; Ribera E
AIDS Rev; 2011; 13(3):180-93. PubMed ID: 21799536
[TBL] [Abstract][Full Text] [Related]
9. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
Grant PM; Zolopa AR
Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
[TBL] [Abstract][Full Text] [Related]
10. New developments in HIV drug resistance.
Cane PA
J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
[TBL] [Abstract][Full Text] [Related]
11. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
12. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
de Béthune MP
Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
[TBL] [Abstract][Full Text] [Related]
13. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.
Wensing AM; van Maarseveen NM; Nijhuis M
Antiviral Res; 2010 Jan; 85(1):59-74. PubMed ID: 19853627
[TBL] [Abstract][Full Text] [Related]
14. Development of anti-retroviral resistance of HIV-1 infected individuals on therapy: is it inevitable?
Kolber MA; Campo RE; Dickinson GM
IUBMB Life; 2004 Jun; 56(6):301-7. PubMed ID: 15370878
[TBL] [Abstract][Full Text] [Related]
15. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
16. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
17. Drug-resistant human immunodefiency virus.
Kozal MJ
Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
[TBL] [Abstract][Full Text] [Related]
18. Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons.
García-Lerma JG
J Antimicrob Chemother; 2005 Aug; 56(2):265-9. PubMed ID: 15951354
[TBL] [Abstract][Full Text] [Related]
19. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
